Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway.

Endothelin-1 (ET-1), a 21-amino acid vasoactive peptide mainly produced by vascular endothelial cells, is involved in the regulation of vascular tone and smooth muscle cell proliferation. Peroxisome proliferator-activated receptors (PPARs), key players in lipid and glucose metabolism, have been implicated in metabolic disorders that are predisposing to atherosclerosis. Because of the potential role of ET-1 in vascular disorders such as hypertension and atherosclerosis, we investigated the regulation of ET-1 expression by PPAR activators. Western blot and reverse transcription-polymerase chain reaction analyses demonstrated that both PPARalpha and PPARgamma are expressed in human coronary artery endothelial cells as well as in endothelial cell lines such as HMEC-1 and ECV304. In bovine aortic endothelial cells and HMEC-1 cells, both PPARalpha and PPARgamma ligands inhibited thrombin-induced ET-1 secretion, whereas basal ET-1 secretion was only slightly suppressed. Reverse transcription-polymerase chain reaction experiments showed that this inhibition of ET-1 production occurs at the gene expression level. Using transient transfection assays, we demonstrated that PPARs downregulate thrombin-activated transcription of the human ET-1 promoter. Transactivation studies with c-Jun and c-Fos expression plasmids indicated that PPARs negatively interfere with the activator protein-1 signaling pathway, which mediates thrombin activation of ET-1 gene transcription. Furthermore, electrophoretic mobility shift assays demonstrated that PPAR activators reduce the thrombin-stimulated binding activity of bovine aortic endothelial cell nuclear extracts as well as c-Jun binding to an activator protein-1 consensus site. Taken together, these data indicate that (1) both PPARalpha and PPARgamma are expressed in human vascular endothelial cells and (2) PPAR activators inhibit thrombin-induced ET-1 biosynthesis, indicating a novel role for PPARs in vascular endothelial function.

[1]  P. Libby,et al.  PPARγ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression PPARγ as a Potential Mediator in Vascular Disease , 1999 .

[2]  P. Libby,et al.  Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. , 1998, Circulation research.

[3]  M. Pfahl,et al.  ET-1 expression and growth inhibition of prostate cancer cells: a retinoid target with novel specificity. , 1998, Cancer research.

[4]  B. Staels,et al.  Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages* , 1998, The Journal of Biological Chemistry.

[5]  A. Nógrádi.  The role of carbonic anhydrases in tumors. , 1998, The American journal of pathology.

[6]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.

[7]  C. Glass,et al.  Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein , 1998 .

[8]  S. Noji,et al.  Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. , 1998, Biochemical and biophysical research communications.

[9]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[10]  E. Levin,et al.  Oestrogen and progesterone inhibit the stimulated production of endothelin-1. , 1998, The Biochemical journal.

[11]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[12]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[13]  A. Muñoz,et al.  Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. , 1997, Genes & development.

[14]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[15]  W. Wahli,et al.  The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.

[16]  J Auwerx,et al.  The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. , 1996, Biochimica et biophysica acta.

[17]  A. V. Van rij,et al.  Endothelin-1 is increased overlying atherosclerotic plaques in human arteries. , 1996, Atherosclerosis.

[18]  J. Lehmann,et al.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.

[19]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[20]  M. Nishizawa,et al.  Suppression of rat glutathione transferase P expression by peroxisome proliferators: interaction between Jun and peroxisome proliferator-activated receptor alpha. , 1995, Cancer research.

[21]  T. Quertermous,et al.  Cooperative interaction of GATA-2 and AP1 regulates transcription of the endothelin-1 gene , 1995, Molecular and cellular biology.

[22]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[23]  M. Dunn,et al.  Thrombin induces the preproendothelin-1 gene in endothelial cells by a protein tyrosine kinase-linked mechanism. , 1995, Circulation research.

[24]  A. Zeiher,et al.  Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes , 1994, The Lancet.

[25]  G. Poirier,et al.  Poly(ADP-ribose) polymerase can bind melphalan damaged DNA. , 1993, Cancer research.

[26]  R. McCarron,et al.  Endothelin induction of adhesion molecule expression on human brain microvascular endothelial cells , 1993, Neuroscience Letters.

[27]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[28]  G. Rao,et al.  Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers. , 1992, Biochemical and biophysical research communications.

[29]  R. Swerlick,et al.  HMEC-1: establishment of an immortalized human microvascular endothelial cell line. , 1992, The Journal of investigative dermatology.

[30]  M. Karin,et al.  Biphasic increase in c-jun mRNA is required for induction of AP-1-mediated gene transcription: differential effects of muscarinic and thrombin receptor activation , 1992, Molecular and cellular biology.

[31]  B. Brenner,et al.  Effects of interferon-gamma on nitric oxide synthase activity and endothelin-1 production by vascular endothelial cells. , 1992, The Journal of clinical investigation.

[32]  T. Horio,et al.  Release mechanism of endothelin-1 and big endothelin-1 after stimulation with thrombin in cultured porcine endothelial cells. , 1992, Journal of vascular research.

[33]  I. Issemann,et al.  The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. , 1992, The EMBO journal.

[34]  T. Quertermous,et al.  Regulation of endothelin-1 gene expression by Fos and Jun. , 1991, The Journal of biological chemistry.

[35]  A. Lerman,et al.  Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. , 1991, The New England journal of medicine.

[36]  S. Kliewer,et al.  Retinoic acid is a negative regulator of AP-1-responsive genes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[37]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[38]  T. Horio,et al.  Thrombin stimulates the production of immunoreactive endothelin-1 in cultured human umbilical vein endothelial cells. , 1990, Metabolism: clinical and experimental.

[39]  Stephan Gebel,et al.  Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone , 1990, Cell.

[40]  D. McTavish,et al.  Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. , 1990, Drugs.

[41]  T. Lüscher,et al.  Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. , 1990, The Journal of clinical investigation.

[42]  Y. Yazaki,et al.  Endothelin stimulates c‐fos and c‐myc expression and proliferation of vascular smooth muscle cells , 1988, FEBS letters.

[43]  N. Ishida,et al.  Cloning and sequence analysis of cDNA encoding the precursor of a human endothelium‐derived vasoconstrictor peptide, endothelin: Identity of human and porcine endothelin , 1988, FEBS letters.

[44]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[45]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[46]  R. Roeder,et al.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.

[47]  D. Gospodarowicz,et al.  Clonal growth of bovine vascular endothelial cells: fibroblast growth factor as a survival agent. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Activators of peroxisome proliferator-activated receptors , 2001 .

[49]  P. Libby,et al.  Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. , 1998, The American journal of pathology.

[50]  W. Wahli,et al.  The PPARalpha-leukotriene B4 pathway to inflammation control. , 1996, Nature.

[51]  A Ward,et al.  Pentoxifylline , 1987, Drugs.